Syros Pharmaceuticals (NASDAQ:SYRS) Stock Rating Upgraded by BidaskClub

Samuel Edwards

Published on:

Syros Pharmaceuticals (NASDAQ:SYRS) was upgraded by stock analysts at BidaskClub from a “sell” rating to a “hold” rating in a report released on Thursday, BidAskClub reports.

SYRS has been the topic of several other research reports. Piper Sandler lifted their price target on shares of Syros Pharmaceuticals from $14.00 to $18.00 in a research report on Friday, August 7th. Roth Capital lifted their price target on shares of Syros Pharmaceuticals from $17.00 to $20.00 and gave the company a “buy” rating in a research report on Monday, October 26th. JMP Securities lifted their price target on shares of Syros Pharmaceuticals from $16.00 to $20.00 and gave the company an “outperform” rating in a research report on Thursday, August 6th. HC Wainwright raised shares of Syros Pharmaceuticals from a “neutral” rating to a “buy” rating and lifted their price target for the company from $11.00 to $15.00 in a research report on Wednesday. Finally, Alliance Global Partners assumed coverage on shares of Syros Pharmaceuticals in a research report on Tuesday, September 22nd. They set a “buy” rating and a $18.00 price target on the stock. Three research analysts have rated the stock with a hold rating, seven have assigned a buy rating and one has issued a strong buy rating to the company. The company currently has an average rating of “Buy” and an average target price of $15.38.

Read Also  Winmark (NASDAQ:WINA) Lowered to Sell at BidaskClub

SYRS opened at $8.26 on Thursday. The company has a debt-to-equity ratio of 0.32, a current ratio of 4.85 and a quick ratio of 4.85. The company’s 50 day simple moving average is $8.60 and its two-hundred day simple moving average is $10.03. Syros Pharmaceuticals has a 1-year low of $4.26 and a 1-year high of $14.69. The firm has a market capitalization of $377.99 million, a price-to-earnings ratio of -4.86 and a beta of 1.85.

Syros Pharmaceuticals (NASDAQ:SYRS) last released its earnings results on Thursday, August 6th. The company reported ($0.38) earnings per share for the quarter, topping the Zacks’ consensus estimate of ($0.40) by $0.02. The business had revenue of $3.19 million for the quarter, compared to analyst estimates of $2.19 million. Syros Pharmaceuticals had a negative net margin of 1,114.79% and a negative return on equity of 94.59%. On average, equities analysts anticipate that Syros Pharmaceuticals will post -1.52 earnings per share for the current fiscal year.

In related news, Director Richard A. Young sold 5,673 shares of Syros Pharmaceuticals stock in a transaction that occurred on Monday, October 19th. The shares were sold at an average price of $8.75, for a total value of $49,638.75. Following the completion of the sale, the director now owns 335,201 shares in the company, valued at approximately $2,933,008.75. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Richard A. Young sold 5,990 shares of the business’s stock in a transaction on Monday, August 17th. The stock was sold at an average price of $12.59, for a total transaction of $75,414.10. Following the completion of the transaction, the director now owns 347,181 shares of the company’s stock, valued at approximately $4,371,008.79. The disclosure for this sale can be found here. Insiders sold a total of 22,933 shares of company stock valued at $254,582 in the last quarter. 14.80% of the stock is owned by insiders.

Read Also  UnitedHealth Group Incorporated (NYSE:UNH) Receives $346.96 Average Target Price from Brokerages

Several large investors have recently bought and sold shares of SYRS. ARK Investment Management LLC grew its stake in shares of Syros Pharmaceuticals by 31.7% in the third quarter. ARK Investment Management LLC now owns 11,212,506 shares of the company’s stock worth $99,119,000 after acquiring an additional 2,699,373 shares in the last quarter. FMR LLC grew its stake in shares of Syros Pharmaceuticals by 5.5% in the second quarter. FMR LLC now owns 6,623,200 shares of the company’s stock worth $70,603,000 after acquiring an additional 344,216 shares in the last quarter. Vanguard Group Inc. grew its stake in shares of Syros Pharmaceuticals by 5.7% in the second quarter. Vanguard Group Inc. now owns 1,901,373 shares of the company’s stock worth $20,269,000 after acquiring an additional 103,005 shares in the last quarter. Two Sigma Advisers LP grew its stake in shares of Syros Pharmaceuticals by 126.7% in the second quarter. Two Sigma Advisers LP now owns 182,300 shares of the company’s stock worth $1,943,000 after acquiring an additional 101,900 shares in the last quarter. Finally, Invesco Ltd. acquired a new position in shares of Syros Pharmaceuticals in the first quarter worth $534,000. Institutional investors and hedge funds own 97.66% of the company’s stock.

Read Also  Motorpoint Group (LON:MOTR) Shares Gap Up to $283.00

About Syros Pharmaceuticals

Syros Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development of treatments for cancer and monogenic diseases, and building a pipeline of gene control medicines. The company’s lead product candidates are SY-1425, a selective retinoic acid receptor alpha agonist, which is in a Phase II clinical trial for genomically defined subset of patients with acute myeloid leukemia and myelodysplastic syndrome; and SY-5609, a cyclin-dependent kinase 7 inhibitor, which is in a Phase I clinical trial in patients with select advanced solid tumors.

Featured Article: Analyst Ratings

Analyst Recommendations for Syros Pharmaceuticals (NASDAQ:SYRS)

Receive News & Ratings for Syros Pharmaceuticals Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Syros Pharmaceuticals and related companies with MarketBeat.com’s FREE daily email newsletter.

Leave a Comment